Seres Therapeutics Inc (MCRB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Seres Therapeutics Inc (MCRB) Financials: Revenue, Profit and Cash Flow
Seres Therapeutics reported revenue of $789.00K for the fiscal year ended Dec 31, 2025. That year, net income was $5.70M with a net margin of 721.9%, operating cash flow was $1.12M and free cash flow was $865.00K. The quarter ended Sep 30, 2026 had revenue of $593.00K and net income of -$16.29M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from $21.77M, a compound annual decline of 30.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $789.00K | N/A | 100.0% | -11910.1% | 721.9% |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2021 | $144.93M | +336.3% | 100.0% | -44.5% | -45.2% |
| Dec 2020 | $33.22M | -3.7% | 100.0% | -265.3% | -268.3% |
| Dec 2019 | $34.51M | +22.1% | 100.0% | -208.3% | -203.7% |
| Dec 2018 | $28.27M | -11.9% | 100.0% | -354.8% | -350.0% |
| Dec 2017 | $32.10M | +47.5% | 100.0% | -284.7% | -278.4% |
| Dec 2016 | $21.77M | N/A | 100.0% | -426.5% | -420.7% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 4091.2% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789.00K | $0 | $0 | $0 | $144.93M | $33.22M | $34.51M | $28.27M | $32.10M | $21.77M |
| Gross profit | $789.00K | $0 | $0 | $0 | $144.93M | $33.22M | $34.51M | $28.27M | $32.10M | $21.77M |
| Research and development | $49.06M | $64.60M | $117.60M | $109.65M | $141.89M | $90.57M | $80.14M | $95.95M | $89.45M | $81.99M |
| Operating income | -$93.97M | -$121.31M | -$195.10M | -$179.91M | -$64.49M | -$88.13M | -$71.88M | -$100.28M | -$91.39M | -$92.84M |
| Net income | $5.70M | $136.00K | -$113.72M | -$250.16M | -$65.58M | -$89.13M | -$70.28M | -$98.94M | -$89.38M | -$91.58M |
| EBITDA | $7.60M | N/A | -$187.82M | -$172.60M | -$56.57M | -$79.57M | -$63.10M | -$92.47M | -$83.50M | -$89.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $593.00K | $736.00K | $358.00K | $438.00K | $351.00K | $0 | $0 | $5.96M | $0 | $0 | $0 | -$125.95M |
| Gross profit | $593.00K | $736.00K | $358.00K | $438.00K | $351.00K | $0 | $0 | -$5.13M | $0 | $0 | $0 | -$125.95M |
| Operating income | -$16.15M | -$21.27M | -$20.91M | -$19.38M | -$22.48M | -$24.88M | -$27.24M | -$28.84M | -$29.17M | -$28.87M | -$34.44M | -$129.47M |
| Net income | -$16.29M | $4.58M | -$19.91M | -$15.34M | $8.20M | -$19.86M | $32.68M | -$15.64M | $88.78M | -$32.87M | -$40.13M | -$41.25M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $10.39M by $35.38M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $138.19M | $139.81M | $358.60M | $348.78M | $354.86M | $342.94M | $132.44M | $120.47M | $189.52M | $272.65M |
| Current assets | $49.38M | $38.67M | $175.41M | $194.76M | $303.63M | $268.78M | $100.19M | $92.67M | $155.08M | $198.37M |
| Cash and equivalents | $45.77M | $30.79M | $127.97M | $163.03M | $180.00M | $116.05M | $65.13M | $85.82M | $36.09M | $54.54M |
| Total liabilities | $93.97M | $126.03M | $403.46M | $338.00M | $223.35M | $168.19M | $180.76M | $168.52M | $128.82M | $140.01M |
| Short-term debt | $10.39M | $8.67M | $5.59M | $456.00K | $0 | $454.00K | $0 | $12.07M | $9.22M | $7.50M |
| Long-term debt | N/A | N/A | $101.54M | $50.59M | $24.64M | $24.64M | $24.65M | N/A | $0 | $0 |
| Shareholder equity | $44.22M | $13.78M | -$44.86M | $10.78M | $131.51M | $174.75M | -$48.32M | -$48.05M | $60.70M | $132.63M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $65.89M | $101.59M | $117.62M | $138.19M | $143.47M | $143.80M | $164.18M | $139.81M | $178.74M | $321.73M | $341.26M | $358.60M |
| Total liabilities | $44.53M | $67.05M | $91.12M | $93.97M | $99.78M | $110.85M | $113.72M | $126.03M | $154.82M | $408.81M | $401.00M | $403.46M |
| Cash and equivalents | $17.53M | $15.59M | $29.83M | $45.77M | $47.64M | $45.38M | $58.85M | $30.79M | $66.82M | $71.23M | $111.18M | $127.97M |
| Shareholder equity | $21.36M | $34.53M | $26.50M | $44.22M | $43.70M | $32.95M | $50.47M | $13.78M | $23.92M | -$87.07M | -$59.74M | -$44.86M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 77.2% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.12M | -$148.61M | -$117.35M | -$228.82M | $6.69M | -$93.61M | -$76.52M | -$62.85M | -$75.52M | $43.92M |
| Capital expenditures | $252.00K | $380.00K | $7.97M | $9.82M | $9.57M | $591.00K | $1.00M | $1.94M | $4.68M | $21.49M |
| Free cash flow | $865.00K | -$148.99M | -$125.33M | -$238.64M | -$2.88M | -$94.20M | -$77.52M | -$64.79M | -$80.20M | $22.43M |
| Investing cash flow | -$42.00K | $142.29M | $10.58M | $82.43M | $64.09M | -$158.89M | -$30.52M | $112.32M | $55.70M | -$65.59M |
| Financing cash flow | $13.90M | -$90.37M | $71.70M | $129.60M | $1.18M | $303.42M | $86.23M | $268.00K | $83.00K | $2.14M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.48M | -$22.39M | -$16.36M | -$14.71M | $2.21M | -$13.29M | $26.91M | -$38.88M | -$34.68M | -$39.81M | -$35.24M | -$47.50M |
| Capital expenditures | N/A | N/A | $0 | $29.00K | $8.00K | $181.00K | $34.00K | $90.00K | $129.00K | $99.00K | $62.00K | $877.00K |
| Free cash flow | N/A | N/A | -$16.36M | -$14.74M | $2.20M | -$13.47M | $26.88M | -$38.97M | -$34.81M | -$39.91M | -$35.30M | -$48.38M |
Frequently Asked Questions About MCRB
What is Seres Therapeutics' annual revenue?
Seres Therapeutics reported revenue of $789.00K for the fiscal year ended Dec 31, 2025.
Is Seres Therapeutics profitable?
Yes. Seres Therapeutics reported net income of $5.70M for the fiscal year ended Dec 31, 2025, with a net margin of 721.9%.
How much free cash flow does MCRB generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.12M minus capital expenditures of $252.00K produced free cash flow of $865.00K.
How much debt does Seres Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $10.39M and cash and equivalents of $45.77M.
What is MCRB's profit margin?
For the fiscal year ended Dec 31, 2025, Seres Therapeutics reported gross margin of 100.0%, operating margin of -11910.1% and net margin of 721.9%.
MCRB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors